Prognostic Value of Ceramide Dynamics in Patients with Acute Coronary Syndrome

A dynamic study of ceramide concentrations and their association with recurrent event risk could enhance our understanding of cardiovascular complications. To assess the prognostic value of ceramide concentrations (Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:1), Cer(d18:1/24:0)) and their dynamics in combination with standard clinical and laboratory parameters and therapeutic interventions in ACS patients. Among 110 ACS patients, triple blood sampling was performed for targeted lipidomic analysis using high-performance liquid chromatography-tandem mass spectrometry. All ceramide concentrations peaked at admission and decreased by the 3rd day of hospitalization and at the 3-month follow-up. The difference between Cer(d18:1/18:0) concentration 3 months after hospital discharge and its baseline value on admission was strongly associated with recurrent events, independent of prior statin treatment. The association of the Cer(d18:1/18:0) change from 3rd day of hospitalization and its baseline concentration on admission with prognosis varied depending on the glycemic profile.